GeneralBullishFortune Crypto · 3h ago7/10
📰
Experimental pill nearly doubles survival time for people with advanced pancreatic cancer. ‘I actually started crying’
Researchers have developed daraxonrasib, an experimental drug that nearly doubles survival time for advanced pancreatic cancer patients by targeting a mutated protein present in over 90% of cases. This breakthrough addresses a protein target that remained untreatable for decades, offering significant hope to patients with one of cancer's most aggressive forms.
